Philips Adjusts Growth Forecast Amid Tariff Pressures and Market Challenges

Dutch health technology company Koninklijke Philips N.V. reported a profit in the fourth quarter of 2025, marking a significant turnaround from a loss in the previous year. The company achieved a net income of 397 million euros, compared to a loss of 333 million euros in the same period last year. Adjusted earnings per share rose to 0.60 euros, up from 0.50 euros a year ago. Fourth-quarter sales increased by 1% to 5.1 billion euros, with comparable sales growth reported at 7%, driven by strong performance across all segments, particularly in North America.

NasdaqReutersBloomberg

Despite the positive fourth-quarter results, Philips has lowered its sales growth forecast for 2026. The company now anticipates comparable sales growth of 3% to 4.5%, down from previous guidance of approximately 4.5%. Philips also set new mid-term financial targets, projecting annual sales growth in the mid-single-digit percentage range and aiming for adjusted EBITA margins to reach the mid-teens by 2028.

Nasdaq

Philips CEO Roy Jakobs acknowledged that U.S. tariffs are significantly impacting profitability, with expectations that tariff pressures will nearly double in 2026. The company is also facing challenges in the Chinese market, where anti-corruption policies and reduced hospital spending have led to declining revenues. Jakobs noted that while the North American market remains a growth engine, the company is cautious about the pace of recovery in China.

Reuters

To counteract the negative effects of tariffs and market fluctuations, Philips is focusing on innovation and operational efficiency. The company has implemented measures to streamline its business and enhance productivity, which have helped offset some of the tariff impacts. Jakobs highlighted that Philips' integration of artificial intelligence across its healthcare products provides a competitive advantage, allowing the company to leverage vast amounts of data generated from its installed base in hospitals.

Bloomberg

Philips' management expressed optimism about the company's direction, with analysts noting that the latest results and outlook indicate improving execution. Barclays analyst Hassan Al-Wakeel remarked that the update serves as a strong foundation for Philips' 2028 strategy. Jakobs emphasized the importance of patient safety and operational simplification as key priorities since he took over as CEO in 2022.

Bloomberg

Despite the positive outlook from management, some analysts remain cautious about the company's ability to navigate ongoing challenges, particularly in the Chinese market and the impact of tariffs. Concerns have also been raised regarding the long-term effects of the recall of sleep apnea devices, which has cost Philips approximately $5 billion and continues to attract scrutiny from regulators.

Bloomberg

• “We clearly see North America as the growth engine,” — Roy Jakobs, CEO of Philips

Bloomberg

• “Today’s update is another proof point of improving execution at the company and we see it as a strong basis to set the 2028 strategy,” — Hassan Al-Wakeel, Barclays Analyst

Bloomberg

Philips is set to present further details on its strategic initiatives and financial outlook during an investor day, where it will outline its plans to achieve sustainable growth amid current market challenges.

Nasdaq